{
    "id": 28149,
    "fullName": "STARD3NL - MET",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "STARD3NL-MET results from the fusion of STARD3NL and MET, and leads to constitutive Met kinase activity and transforming ability in culture (PMID: 29284707). STARD3NL-RET fusions have been identified in lung adenocarcinoma (PMID: 29284707).",
            "references": [
                {
                    "id": 11323,
                    "pubMedId": 29284707,
                    "title": "Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29284707"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 83930,
        "geneSymbol": "STARD3NL",
        "terms": [
            "STARD3NL",
            "MENTHO"
        ]
    },
    "variant": "STARD3NL - MET",
    "createDate": "05/03/2018",
    "updateDate": "12/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4233,
                "geneSymbol": "MET",
                "terms": [
                    "MET",
                    "AUTS9",
                    "c-Met",
                    "DFNB97",
                    "HGFR",
                    "RCCP2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 13878,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in a partial response with 69% tumor size reduction in a patient with lung adenocarcinoma harboring STARD3NL-MET fusion (PMID: 29284707).",
            "molecularProfile": {
                "id": 29721,
                "profileName": "STARD3NL - MET"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11323,
                    "pubMedId": 29284707,
                    "title": "Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29284707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) inhibited Met signaling and growth of transformed cells expressing STARD3NL-MET fusion in culture (PMID: 29284707).",
            "molecularProfile": {
                "id": 29721,
                "profileName": "STARD3NL - MET"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11323,
                    "pubMedId": 29284707,
                    "title": "Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29284707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited Met signaling and growth of transformed cells expressing STARD3NL-MET fusion in culture (PMID: 29284707).",
            "molecularProfile": {
                "id": 29721,
                "profileName": "STARD3NL - MET"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11323,
                    "pubMedId": 29284707,
                    "title": "Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29284707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29721,
            "profileName": "STARD3NL - MET",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}